SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Therefore, this study aimed to examine the effects of the SGLT2 inhibitor dapagliflozin on obesity and its comorbidities such as NAFLD in high-fat-diet (HFD)-induced obese (DIO) mice.